Gene Therapy Improves Symptoms in Mouse Model of Charcot–Marie–Tooth Disease
Author Information
Author(s): Ozes Burcak, Tong Lingying, Moss Kyle, Myers Morgan, Morrison Lilye, Attia Zayed, Sahenk Zarife
Primary Institution: The Abigail Wexner Research Institute, Nationwide Children’s Hospital
Hypothesis
Can AAV1.NT-3 gene therapy improve the phenotype in a mouse model of Charcot–Marie–Tooth Type 4C?
Conclusion
AAV1.NT-3 gene therapy significantly improved functional and electrophysiological outcomes in the Sh3tc2−/− mouse model of CMT4C.
Supporting Evidence
- NT-3 gene therapy improved functional outcomes such as rotarod and grip strength.
- Electrophysiological studies showed increased nerve conduction velocity in treated mice.
- Histopathological analysis revealed improved myelination and Schwann cell density.
Takeaway
Scientists used a special gene therapy to help sick mice with a nerve disease feel better and move better.
Methodology
The study involved injecting AAV1.NT-3 into the muscles of Sh3tc2−/− mice and assessing their functional and electrophysiological outcomes over six months.
Limitations
The study was conducted in a mouse model, which may not fully replicate human conditions.
Participant Demographics
The study involved 15 Sh3tc2−/− mice (7 females and 8 males) and 16 control mice (8 females and 8 males).
Statistical Information
P-Value
0.0014
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website